Illumina Names Agilent Executive Jacob Thaysen as New CEO

September 05, 2023: Illumina, Inc. (NASDAQ: ILMN), a leading provider of genetic sequencing and array-based technologies, announced on Tuesday that it has appointed Jacob Thaysen as its new CEO, effective September 25, 2023. Thaysen will succeed Francis deSouza, who will step down after ten years as CEO.

Thayersen is currently the president of Agilent Technologies’ Life Sciences and Applied Markets Group. He has over 25 years of experience in the life sciences industry and has held leadership positions at companies such as Thermo Fisher Scientific and Life Technologies.

In a statement, Illumina’s board of directors said that Thaysen was selected for his “deep knowledge of the life sciences industry, his proven track record of leadership, and his passion for innovation.”

Thayersen said he was “excited to join Illumina at such a pivotal time in the company’s history.” He added that he is “committed to building on Illumina’s strong foundation and leading the company into its next era of growth.”

The appointment of Thaysen as CEO is a sign of Illumina’s focus on innovation and growth. Thaysen is a strong leader who deeply understands the life sciences industry. He is well-positioned to lead Illumina into its next era of change.

Actionable Takeaways:

• Investors interested in Illumina should keep an eye on the company’s innovation pipeline and growth prospects.
• Illumina’s customers should know the company’s commitment to innovation and plans to expand its product offerings.

Practical Takeaways for Businesses:

• Businesses that use Illumina’s products and services should stay up-to-date on the company’s latest innovations.
• Businesses considering using Illumina’s products and services should contact the company to learn more about its offerings.

The appointment of Thaysen as CEO is a positive sign for Illumina. The company is well-positioned for growth under his leadership.